BAM
CTMX icon

Byrne Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Byrne Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,000
Closed -$12.4K – 541
2023
Q4 		$12.4K Hold
8,000
– – 0.01% 336
2023
Q3 		$10K Hold
8,000
– – 0.01% 336
2023
Q2 		$14K Buy
8,000
+400
+5% +$664 0.01% 368
2023
Q1 		$11K Sell
7,600
-6,500
-46% -$14.7K 0.01% 374
2022
Q4 		$22.6K Buy
+14,100
New +$20.9K 0.02% 308

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Byrne Asset Management's CTMX Position: Q1 2024 in Review

Byrne Asset Management sold out of CytomX Therapeutics (CTMX) in Q1 2024, closing a stake of 8,000 shares — an estimated $12.4K sold.

Byrne Asset Management first reported a position in CTMX in Q4 2022 and held it in 5 quarters. The position peaked at $22.6K in Q4 2022. 88 funds tracked by Wall St. Rank hold CTMX as of Q1 2024.

  • Byrne Asset Management reported no remaining CytomX Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Byrne Asset Management sold 8,000 CytomX Therapeutics shares in Q1 2024, an estimated $12.4K.
  • Byrne Asset Management first reported a position in CytomX Therapeutics in Q4 2022 and held it in 5 quarters.
  • Byrne Asset Management's CytomX Therapeutics position peaked at $22.6K in Q4 2022.
  • 88 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2024.

Based on Byrne Asset Management's 13F filing for Q1 2024, filed 22 Apr 2024.